[go: up one dir, main page]

NO20052400L - Kontrollert frigivelsespreparat - Google Patents

Kontrollert frigivelsespreparat

Info

Publication number
NO20052400L
NO20052400L NO20052400A NO20052400A NO20052400L NO 20052400 L NO20052400 L NO 20052400L NO 20052400 A NO20052400 A NO 20052400A NO 20052400 A NO20052400 A NO 20052400A NO 20052400 L NO20052400 L NO 20052400L
Authority
NO
Norway
Prior art keywords
granule
active ingredient
release
controlled
release preparation
Prior art date
Application number
NO20052400A
Other languages
English (en)
Other versions
NO342002B1 (no
Inventor
Yohko Akiyama
Hiroto Bando
Takashi Kurasawa
Naoki Nagahara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32109465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052400(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20052400L publication Critical patent/NO20052400L/no
Priority to NO20180072A priority Critical patent/NO343175B1/no
Publication of NO342002B1 publication Critical patent/NO342002B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kontrollert frigivelsespreparat hvori frigivelse av aktiv ingrediens konttolleres, som fiigir en aktiv ingrediens i en forlenget tidsperiode ved å bli værende eller sette ned migrering i gastiointestinal ttakten, er tilveiebrakt ved hjelp av innkapsling av en tablett, granul eller fingranul, hvori fiigivelse av aktiv ingrediens kontiolleres, og en gel dannende polymer. Nevnte tablett, granul eller fingranul har et frigivelseskonttollert belegg dannet på en kjemepartikkel som irmeholder en aktiv ingrediens.
NO20052400A 2002-10-16 2005-05-13 Kontrollert frigivelsespreparat NO342002B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20180072A NO343175B1 (no) 2002-10-16 2018-01-17 Tablett, granul eller fingranul hvor frigivelse av aktiv ingrediens kontrolleres omfattende en imidazolforbindelse, samt kapsel og utvidet frigivelseskapsel omfattende nevnte tablett, granul eller fingranul

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002301876 2002-10-16
JP2003066336 2003-03-12
PCT/JP2003/013155 WO2004035020A2 (en) 2002-10-16 2003-10-15 Controlled release preparation

Publications (2)

Publication Number Publication Date
NO20052400L true NO20052400L (no) 2005-05-13
NO342002B1 NO342002B1 (no) 2018-03-12

Family

ID=32109465

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052400A NO342002B1 (no) 2002-10-16 2005-05-13 Kontrollert frigivelsespreparat
NO20180072A NO343175B1 (no) 2002-10-16 2018-01-17 Tablett, granul eller fingranul hvor frigivelse av aktiv ingrediens kontrolleres omfattende en imidazolforbindelse, samt kapsel og utvidet frigivelseskapsel omfattende nevnte tablett, granul eller fingranul

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20180072A NO343175B1 (no) 2002-10-16 2018-01-17 Tablett, granul eller fingranul hvor frigivelse av aktiv ingrediens kontrolleres omfattende en imidazolforbindelse, samt kapsel og utvidet frigivelseskapsel omfattende nevnte tablett, granul eller fingranul

Country Status (27)

Country Link
US (7) US7790755B2 (no)
EP (3) EP2277510B1 (no)
JP (2) JP5330967B2 (no)
KR (3) KR101061750B1 (no)
CN (1) CN101884629B (no)
AR (1) AR041562A1 (no)
AU (2) AU2003272098B2 (no)
BR (2) BRPI0315142B8 (no)
CA (2) CA2737851C (no)
CR (2) CR10284A (no)
CY (1) CY1114599T1 (no)
DK (1) DK1553929T3 (no)
ES (1) ES2410812T5 (no)
IL (1) IL167447A (no)
MA (1) MA27456A1 (no)
MX (2) MX337937B (no)
MY (2) MY148805A (no)
NO (2) NO342002B1 (no)
NZ (2) NZ552592A (no)
OA (1) OA13143A (no)
PE (3) PE20110544A1 (no)
PL (2) PL219122B1 (no)
PT (1) PT1553929E (no)
SG (1) SG164281A1 (no)
SI (1) SI1553929T1 (no)
TW (2) TWI378794B (no)
WO (1) WO2004035020A2 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US8449911B2 (en) 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
TW200606163A (en) 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
JP5124267B2 (ja) * 2005-02-25 2013-01-23 武田薬品工業株式会社 顆粒の製造方法
US8828429B2 (en) * 2005-03-03 2014-09-09 Takeda Pharmaceutical Company Limited Release-control composition
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
CN101351232A (zh) * 2005-12-28 2009-01-21 巴斯夫欧洲公司 用于生产吸水性材料的方法
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
JP5314004B2 (ja) * 2007-05-08 2013-10-16 ダウ グローバル テクノロジーズ エルエルシー 水分散性ポリマー組成物
CA2702356C (en) * 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
CA2738458A1 (en) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
MY173730A (en) 2008-03-11 2020-02-18 Takeda Pharmaceuticals Co Orally-disintegrating solid preparation
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
FR2938432B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus
US20130273171A1 (en) * 2009-11-20 2013-10-17 Handa Pharmaceuticals, Llc Oral formulation for dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
CA3224506A1 (en) 2010-05-12 2011-11-17 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
HUE035763T2 (en) * 2010-06-08 2018-05-28 Kobe Gakuin Educational Found Method of producing coated particles and coated particles
US9248119B2 (en) 2010-06-16 2016-02-02 Takeda Pharmaceuticals U.S.A., Inc. Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
US20120164233A1 (en) 2010-07-30 2012-06-28 Ranbaxy Laboratories Limited Pulsatile release pharmaceutical formulation of dexlansoprazole
US20120201886A1 (en) * 2010-07-30 2012-08-09 Micro Labs Limited Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
UA112855C2 (uk) * 2010-12-29 2016-11-10 Др. Редді'С Лабораторіс Лтд. Композиції бензімідазолів з модифікованим вивільненням
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CN103442727B (zh) 2011-02-11 2016-08-10 Zx制药有限责任公司 多微粒l-薄荷醇制剂及相关方法
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
UY34403A (es) 2011-10-21 2013-05-31 Takeda Pharmaceutical Preparación de liberación sostenida
US20140330192A1 (en) * 2012-02-13 2014-11-06 The Ex Plant Company Dressing for application to a wound or burn
US20130209592A1 (en) * 2012-02-13 2013-08-15 Steven C. Denstman Plant Extract Based Compositions and Methods For Treating Chronic Wounds
BR112015026283B1 (pt) 2013-04-23 2023-04-25 Société des Produits Nestlé S.A. Composição multiparticulada, método para fabricação da mesma e uso de uma pluralidade de núcleos com revestimentos entéricos individuais contendo um ou mais ingredientes ativos com base em terpeno
KR20160081322A (ko) 2014-12-31 2016-07-08 삼아제약 주식회사 양성자 펌프 억제제를 유효성분으로 포함하며 방출이 제어된 약제학적 조성물
KR101907116B1 (ko) * 2016-07-25 2018-10-11 한미약품 주식회사 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
CN107648231B (zh) * 2016-07-25 2021-07-16 江苏豪森药业集团有限公司 右兰索拉唑药物制剂
KR101877350B1 (ko) * 2016-10-28 2018-08-09 한미약품 주식회사 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
KR102727681B1 (ko) 2019-02-08 2024-11-07 주식회사유한양행 덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN111909044A (zh) * 2019-05-09 2020-11-10 南京爱德程医药科技有限公司 2-(烷基氨基)乙基苯甲酸酯类化合物的合成方法
JP7714473B2 (ja) * 2019-05-31 2025-07-29 デナリ セラピューティクス インコーポレイテッド ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法
US11839622B1 (en) 2020-01-15 2023-12-12 Randall Lewarchik Consumable nutraceutical composition
KR102471545B1 (ko) 2020-11-20 2022-11-29 서울대학교 산학협력단 덱스란소프라졸을 유효성분으로 포함하는 pH 의존성 타블렛-인-캡슐 복합제제 및 이의 제조방법
CN117320554A (zh) * 2021-03-11 2023-12-29 碗中动物健康公司 用于控制犬科动物中蜱侵袭的口服犬科动物饲料和方法
CN117412673A (zh) * 2021-03-11 2024-01-16 碗中动物健康公司 犬科动物口服饲料和在犬科动物中控制蚤侵袭的方法
KR102803742B1 (ko) 2022-07-25 2025-05-13 주식회사 와이에스생명과학 덱스란소프라졸 함유 정제
EP4356904A1 (en) * 2022-10-19 2024-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. A capsule comprising lansoprazole
KR20250167303A (ko) 2024-05-22 2025-12-01 한국유나이티드제약 주식회사 약제학적 제제

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4649043A (en) 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
ZA854287B (en) 1984-06-16 1986-02-26 Byk Gulden Lomberg Chem Fab Dialkoxypyridines,process for their preparation,their use and medicaments containing them
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
KR890000387B1 (ko) 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
IL76839A (en) 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
SE8505112D0 (sv) 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
JPH07121859B2 (ja) 1986-03-18 1995-12-25 第一製薬株式会社 徐放性カプセル剤
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0643426B2 (ja) 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH0674272B2 (ja) 1986-11-13 1994-09-21 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
JPH0832625B2 (ja) 1987-01-29 1996-03-29 武田薬品工業株式会社 有核顆粒およびその製造法
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JP2549119B2 (ja) 1987-05-30 1996-10-30 三省製薬株式会社 外用剤
JP2602518B2 (ja) * 1988-01-27 1997-04-23 エーザイ株式会社 被覆された胃酸分泌抑制剤含有組成物
DE3822095A1 (de) 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US4980172A (en) * 1989-05-12 1990-12-25 Fey Michael S Anti-smoking oral composition
FR2655266B1 (fr) 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
EP0546593B1 (en) 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
NZ255579A (en) 1992-09-18 1996-03-26 Yamanouchi Pharma Co Ltd Sustained release hydrogel pharmaceutical formulation
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SI1078628T1 (sl) 1994-07-08 2009-04-30 Astrazeneca Ab Večenotska tabletirana dozirna oblika
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
DK0859612T3 (da) * 1995-09-21 2003-09-22 Pharma Pass Ii Llc Farmaceutisk sammensætning indeholdende en syre-labil omeprazol og fremgangsmåde til fremstilling deraf
US5567144A (en) * 1995-10-05 1996-10-22 Desa International Inc. Hot surface ignition controller for fuel oil burner
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE69722191T2 (de) 1996-03-08 2004-04-01 Nycomed Danmark Aps Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
CA2275604A1 (en) 1997-01-03 1998-07-09 Kenneth Iain Cumming Sustained release cisapride mini-tablet formulation
US6162463A (en) 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
DE19742711C1 (de) * 1997-09-26 1999-05-20 Intec Bielenberg Gmbh & Co Kg Vorrichtung zum Aufbringen von Klebepunkten auf ein Substrat
KR100387245B1 (ko) 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
BR9813548A (pt) 1997-12-12 2000-10-10 Samyang Corp Micelas poliméricas misturadas biodegradáveis para distribuição de gene
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
CA2320963A1 (en) 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
WO1999053918A1 (en) 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
DE19820529A1 (de) 1998-05-08 1999-11-11 Lohmann Therapie Syst Lts Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
TW585786B (en) 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
IT1301947B1 (it) 1998-07-28 2000-07-20 Chiesi Farma Spa Formulazioni farmaceutiche di beclometasone dipropionato per iltrattamento di malattie infiammatorie croniche della mucosa
US6093734A (en) 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
DK1105105T3 (da) 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
JP2000119181A (ja) 1998-10-06 2000-04-25 Kureha Chem Ind Co Ltd エスクレチン及びその誘導体の放出制御経口製剤
RU2236847C2 (ru) 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
IL131508A (en) 1999-08-19 2006-12-10 David Cohen Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants
WO2001013898A2 (en) 1999-08-26 2001-03-01 Elan Corporation, Plc. Pharmaceutical formulations with different release times
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
ATE284205T1 (de) 1999-10-01 2004-12-15 Natco Pharma Ltd Magensaftresistente gelartige weichkapsel
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
CA2680292C (en) 1999-11-02 2012-11-27 Basilea Pharmaceutica Ag Intermediates useful for the preparation of n-substituted carbamoyloxyalkyl-azolium derivatives
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
IT1318376B1 (it) 2000-03-07 2003-08-25 Pharmatec Internat S R L Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo.
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
ES2273829T3 (es) 2000-04-28 2007-05-16 Takeda Pharmaceutical Company Limited Procedimiento para producir derivado de sulfoxido opticamente activo.
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
TWI232761B (en) * 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
WO2002017887A1 (de) 2000-08-29 2002-03-07 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US20040039027A1 (en) 2000-10-12 2004-02-26 Keiji Kamiyama Benzimidazole compounds, process for producing the same and use thereof
JP2002187890A (ja) 2000-10-12 2002-07-05 Takeda Chem Ind Ltd ベンズイミダゾール化合物、その製造法およびその用途
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
SI20720A (sl) 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
PL201766B1 (pl) 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie
ITMI20010220A1 (it) 2001-02-05 2002-08-05 Valpharma Sa Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
DK1429734T3 (da) * 2001-09-21 2008-05-13 Egalet As Faste dispersioner af carvedilol til kontrolleret afgivelse
WO2003027098A1 (en) 2001-09-25 2003-04-03 Takeda Chemical Industries, Ltd. Benzimidazole compound, process for producing the same, and use thereof
AU2003238896A1 (en) 2002-06-07 2003-12-22 Geneva Pharmaceuticals, Inc. Stabilized pharmaceutical compositions containing benzimidazole compounds
ES2645930T3 (es) 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas

Also Published As

Publication number Publication date
BRPI0315142B8 (pt) 2021-05-25
PE20110544A1 (es) 2011-08-25
JP5746722B2 (ja) 2015-07-08
CR20110373A (es) 2011-08-24
US20100278911A1 (en) 2010-11-04
TW201125563A (en) 2011-08-01
WO2004035020A2 (en) 2004-04-29
JP5330967B2 (ja) 2013-10-30
KR101061750B1 (ko) 2011-09-02
AU2009243408A1 (en) 2009-12-17
AU2003272098A1 (en) 2004-05-04
MA27456A1 (fr) 2005-07-01
CA2737851C (en) 2013-04-30
CA2499574A1 (en) 2004-04-29
PL218177B1 (pl) 2014-10-31
BR0315142B1 (pt) 2018-01-09
EP2283827A1 (en) 2011-02-16
EP1553929B2 (en) 2016-11-16
IL167447A (en) 2015-07-30
PL376222A1 (en) 2005-12-27
US20160128945A1 (en) 2016-05-12
DK1553929T3 (da) 2013-05-13
KR20120034809A (ko) 2012-04-12
EP2277510B1 (en) 2018-12-26
MY148805A (en) 2013-05-31
CR10284A (es) 2008-10-17
ES2410812T3 (es) 2013-07-03
US20100285120A1 (en) 2010-11-11
BR122016030094B8 (pt) 2021-05-25
CN101884629A (zh) 2010-11-17
AU2009243408B2 (en) 2012-01-19
CN101884629B (zh) 2013-08-21
US7790755B2 (en) 2010-09-07
PT1553929E (pt) 2013-04-23
NZ552592A (en) 2007-06-29
KR20050072108A (ko) 2005-07-08
HK1080378A1 (en) 2006-04-28
US8784885B2 (en) 2014-07-22
US20140186448A1 (en) 2014-07-03
EP2277510A2 (en) 2011-01-26
JP2010077144A (ja) 2010-04-08
SI1553929T1 (sl) 2013-07-31
KR101401913B1 (ko) 2014-05-30
WO2004035020A3 (en) 2004-06-24
EP2283827B1 (en) 2019-10-02
PE20050102A1 (es) 2005-04-05
CA2737851A1 (en) 2004-04-29
TWI347202B (en) 2011-08-21
PE20090076A1 (es) 2009-03-02
SG164281A1 (en) 2010-09-29
EP2277510A3 (en) 2012-02-01
US20060013868A1 (en) 2006-01-19
AU2003272098B2 (en) 2009-12-10
MXPA05003902A (es) 2005-06-22
MX337937B (es) 2016-03-29
NO20180072A1 (no) 2005-05-13
MY169471A (en) 2019-04-12
CA2499574C (en) 2011-07-05
JP2013155181A (ja) 2013-08-15
OA13143A (en) 2006-12-13
TWI378794B (en) 2012-12-11
BR122016030094B1 (pt) 2020-06-23
EP1553929A2 (en) 2005-07-20
US8722084B2 (en) 2014-05-13
NO343175B1 (no) 2018-11-26
US20140186449A1 (en) 2014-07-03
PL219122B1 (pl) 2015-03-31
TW200502006A (en) 2005-01-16
KR20100132082A (ko) 2010-12-16
BR0315142A (pt) 2005-08-09
EP1553929B1 (en) 2013-03-27
ES2410812T5 (es) 2017-05-12
AR041562A1 (es) 2005-05-18
NZ539353A (en) 2007-07-27
CY1114599T1 (el) 2016-10-05
US20100272798A1 (en) 2010-10-28
NO342002B1 (no) 2018-03-12

Similar Documents

Publication Publication Date Title
NO20052400L (no) Kontrollert frigivelsespreparat
RU2012136839A (ru) Композиции для ухода за полостью рта и устранения неприятного запаха
DE69626117D1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2007092179A3 (en) Device with nanocomposite coating for controlled drug release
JP2005502430A5 (no)
WO2007149539A3 (en) Freeze-thaw method for modifying stent coating
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
JP2009534294A5 (no)
EA201390981A1 (ru) Разрушающаяся во рту таблетка
WO2006023286A3 (en) Controlled release nanoparticle active agent formulation dosage forms and methods
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
MX2007006343A (es) Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica.
NO20070559L (no) Granuler for kontrollert frigjoring av tamsulosin
BR0315604A (pt) Composição de liberação controlada para administração oral de drogas
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
NO20050771L (no) Bicifadinformulering
NO20031211L (no) Plaster omfattende diclofenac
NO20043059L (no) Fremgangsmate for gradvis deformering av en Boole'sk modell som simulerer et heterogent medium, begrenset til dynamiske data
ATE213933T1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff
WO2007143959A3 (en) Tablet containing metformin
WO2008065107A8 (en) Storage stable tablets based on benzimidazole derivatives coated with a gastro-resistant film
ATE449598T1 (de) Geschmacksmaskierte orale zubereitung von telithromycin

Legal Events

Date Code Title Description
MK1K Patent expired